ALVO

Investor Moves

Name	Value	Action	Change	Price	Current Price
Howard MarksOaktree Capital $13M1.6M shares TrimQ3 2025 $1.5M $8.53 $3.44

News

globenewswire.comAlvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placementglobenewswire.comJun 18

globenewswire.comAlvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Sharesglobenewswire.comJun 18

globenewswire.comAlvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placementglobenewswire.comJun 15

globenewswire.comAlvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Sharesglobenewswire.comJun 15

globenewswire.comTransactions of Managers and Closely Associated Personsglobenewswire.comJun 10

Trade ALVO

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

CEO: Lisa Graver
IPO Date: Jun 16, 2022

Market Data

Open: $3.68
High: $3.73
Low: $3.48
Volume: 691.5K
52W High: $11.12
52W Low: $2.94

Valuation

Market Cap: $1.1B
Enterprise Value: $2.5B

Financials

Free Cash Flow: $-115M
Revenue: $586M
Net Income: $28M
Cash: $172M
Debt: $1.4B

Events

EarningsAug 12

EPS est. -0.04